Australian Biotechnology News
Latest stories
  • +

    Halcygen (ASX:HGN) to expand board following departure of director and COO 30/07/2010 13:21:00

    Halcygen’s Executive Director and COO, Craig Bottomley, steps down as company plans to expand board and drive sales in Australia and overseas.
    Melbourne-based generic pharmaceutical manufacturer, Halcygen Pharmaceuticals (ASX:HGN), is seeking to add new talent to its board and senior management following the departure of Executive Director and COO, Craig Bottomley yesterday.
  • +

    Patrys adds to antibody portfolio 29/07/2010 13:47:00

    PAM-1 shown to reduce gastric and pancreatic tumours
    Human antibody therapy specialists Patrys announced today that is has acquired a new anti-cancer antibody which has been shown to significantly reduce gastric and pancreatic tumours in animal models of human cancers.
  • +

    Study shows antibiotics could help fight malaria 29/07/2010 13:20:00

    Potential for malaria to be contained in high-risk populations, particularly children
    In a major breakthrough for malaria treatment European researchers have shown that mice infected with the disease administered antibiotics developed immunity against re-infection.
  • +

    Australian Life Scientist July/August edition out now 28/07/2010 15:36:00

    The Human Proteome Organisation (HPUO) 2010 World Congress and the Human Proteome Project feature in this issue, along with proteomics, synthetic biology, genetics and genomics, and next generation genome sequencing.
    The July/August edition of Australian Life Scientist is out now. The issue takes an in-depth look at the happenings at the upcoming Human Proteome Organisation (HPUO) 2010 World Congress, which will host the launch of the long awaited Human Proteome Project.
  • +

    Hurdles remain for Botox as a migraine treatment 28/07/2010 14:28:00

    Clincal trial setback while high costs point to reimbursement restrictions
    Botox was approved in the UK this month for the treatment of migraines, however, the high costs of the cosmetic treatment as well as lingering safety concerns may restrict its ability to penetrate this new market.
  • +

    Sigma names Jeff Sells as company CFO 28/07/2010 17:46:00

    Former treasurer inherits shaky financials and a retreating suitor
    Beleaguered Victorian biotech Sigma Pharmaceuticals has appointed former group treasurer Jeff Sells as its new CFO.
More >AgBiotech
  • +

    SA scientist pioneers new system for organic waste 17/06/2010 22:58:00

    Conversion of organic waste into feedstock, energy and irrigation water.
    A biotechnologist from the South Australian Research and Development Institute ( SARDI ) has demonstrated a unique ‘waste-food-chain’ with major implications for industries that product organic waste.
  • +

    Government announces $440,000 to bolster overseas collaborations 08/06/2010 13:30:00

    Study into octopus venom for pain and cancer among 69 programs to receive new funding
    The federal government has announced new funding of $440,000 to support 69 research collaborations between Australian and overseas groups, as part of the International Science Linkages – Science Academies Program.
More >Biomedical
  • +

    Patrys adds to antibody portfolio 29/07/2010 13:47:00

    PAM-1 shown to reduce gastric and pancreatic tumours
    Human antibody therapy specialists Patrys announced today that is has acquired a new anti-cancer antibody which has been shown to significantly reduce gastric and pancreatic tumours in animal models of human cancers.
  • +

    Study shows antibiotics could help fight malaria 29/07/2010 13:20:00

    Potential for malaria to be contained in high-risk populations, particularly children
    In a major breakthrough for malaria treatment European researchers have shown that mice infected with the disease administered antibiotics developed immunity against re-infection.
More >Bioinformatics
  • +

    Biota Holdings targeting asthma market with anti-viral drug 27/07/2010 18:45:00

    US clinical trial of anti-viral BTA798 to treat human rhinovirus to coincide with onset of northern hemisphere flu season.
    Biota Holdings today commenced a 400-member trial in the US of its anti-viral drug BTA798 on sufferers of asthma who present with cold symptoms.
  • +

    Feature: Towards the $1000 genome 27/07/2010 16:05:00

    The $1000 genome is no longer just a lofty aspiration. The next generation of massively parallel, benchtop sequencers could see it realised within two years.
    The $1000 genome is no longer just a lofty aspiration. The next generation of massively parallel, benchtop sequencers could see it realised within two years.
Additional Resources
Newsletter Subscription
Sign up for our Australian Life Scientist newsletters!
Subscribe now!
 
Jobs